Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Operating Leases (2019 - 2025)

Syndax Pharmaceuticals has reported Operating Leases over the past 7 years, most recently at $1.5 million for Q4 2025.

  • Quarterly results put Operating Leases at $1.5 million for Q4 2025, down 25.77% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (down 25.77% YoY), and the annual figure for FY2025 was $1.5 million, down 25.77%.
  • Operating Leases for Q4 2025 was $1.5 million at Syndax Pharmaceuticals, down from $2.0 million in the prior quarter.
  • Over the last five years, Operating Leases for SNDX hit a ceiling of $2.0 million in Q4 2024 and a floor of $22000.0 in Q2 2021.
  • Median Operating Leases over the past 5 years was $676000.0 (2022), compared with a mean of $715187.5.
  • Biggest five-year swings in Operating Leases: tumbled 90.83% in 2021 and later soared 2490.91% in 2022.
  • Syndax Pharmaceuticals' Operating Leases stood at $711000.0 in 2021, then dropped by 0.28% to $709000.0 in 2022, then dropped by 18.48% to $578000.0 in 2023, then surged by 254.5% to $2.0 million in 2024, then fell by 25.77% to $1.5 million in 2025.
  • The last three reported values for Operating Leases were $1.5 million (Q4 2025), $2.0 million (Q4 2024), and $133000.0 (Q2 2024) per Business Quant data.